Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olinciguat
- Development stage
- Phase 2
- Lead developer
- Cyclerion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olinciguat is an orally bioavailable small molecule that acts as a stimulator of soluble guanylate cyclase (sGC), developed by Cyclerion Therapeutics, a spin-off from Ironwood Pharmaceuticals. It enhances the nitric oxide (NO)-dependent catalytic activity of sGC, increasing the formation of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP). This leads to vasodilation, anti-inflammatory effects, and improved blood flow by promoting NO/cGMP-mediated muscle relaxation and suppressing leukocyte-endothelial interactions. Olinciguat has been investigated for cardiovascular disorders, fibrosis, sickle cell anemia, and gastrointestinal diseases. It received orphan drug designation for sickle cell anemia but development in this indication has been discontinued[3][7][5].
- Other names
- olinciguat [INN]olinciguat [USAN]
02
Targets
sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on olinciguat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olinciguat.